Browse > Article
http://dx.doi.org/10.5352/JLS.2021.31.7.631

Determination of Optimal Dosage of Ethanol Extract of Houttuynia cordata Thunberg Against Benign Prostatic Hyperplasia  

Lee, Jin Young (Department of Pharmacy, Kyungsung University)
Kim, Hyung Hoi (Biomedical Research Institute, Busan National University Hospital)
Kang, Jae Seon (Department of Pharmacy, Kyungsung University)
Publication Information
Journal of Life Science / v.31, no.7, 2021 , pp. 631-640 More about this Journal
Abstract
Houttuynia cordata Thunberg has been studied for a variety of pharmacological actions in traditional oriental medicine. In this study, we investigated the effects of Houttuynia cordata ethanol extract (HCE) on benign prostatic hyperplasia (BPH) models induced by castration and testosterone propionate (TP) injection. Thirty rats were divided into six groups. One group was used as a normal control, and the other groups were castrated and had intraperitoneal injections of TP for 14 days to induce BPH. A positive control group was given daily doses of finasteride (5 mg/kg) to the BPH model. Rats administered HCE (0.5, 1 or 2 mg/kg) instead of finasteride were compared with controls as experimental groups. There was no statistical significance in terms of prostate weight based on 100 g of body weight. The concentrations of 5-α reductase and dehydroxytestosteronre (DHT) were determined via ELISA tests, and there was a significant decrease in all experimental groups. The 0.5 mg/kg HCE group had the lowest level of 5-α reductase, and the 2 mg/kg HCE group had the lowest level of DHT. In the histopathological observation of prostates, the control and the 2 mg/kg HCE groups had normal cell shapes and no swelling. However, in the negative control group and the 1 mg/kg HCE group, the cells were swollen, and the gap between the cells was narrowed. In particular, in the 0.5 mg/kg HCE group, some cells were bursting. Therefore, the administration of more than 2 mg/kg of HCE is suitable to protect against BPH.
Keywords
Benign prostatic hyperplasia (BPH); finasteride; houttuynia cordata Thunberg; prostate; testosterone propionate (TP);
Citations & Related Records
연도 인용수 순위
  • Reference
1 Kwon, D. H., Hwangbo, H., Choi, E. O., Kim, M. Y., Ji, S. Y., Kim, K. I., Park, N. J., Kim, S. O., Hong, S. H., Park, C., Hwang, H. J., Jeong, J. S. and Choi, Y. H. 2018. Effects of Corni Fructus on testosterone-induced benign prostatic hyperplasia in sprague dawley rats. J. Life Sci. 28, 1507-1515.   DOI
2 Lee, S. J., Choi, H. R., Lee, J. H., Kwon, J. W., Lee, H. K., Jeong, J. T. and Lee, T. B. 2014. Effects of unripe black raspberry extracts on prostate cancer cell line and rat model of benign prostatic hyperplasia. J. Kor. Soc. Food Sci. Nutr. 43, 507-515.   DOI
3 Park, D. J., Kang, S. H. and Cho, Y. H. 2006. The antihyperplastic effect of oral catechin ingestion in a rat model of benign prostatic hyperplasia. Kor. J. Urol. 47, 1289-1293.   DOI
4 Park, H. S., Chang, N. S., Kim, E. J., Yun, H. N., Lee, H. J., Lee, B. E., Kim, H. H., Kwon, S. W. and Jeong, Y. J. 2004. Association between nutrient intakes and benign prostate hyperplasia. Kor. J. Nutr. 37, 801-808.
5 Roehrborn, C. G. 2008. Pathology of benign prostatic hyperplasia. Int. J. Impot. Res. 20, 11-18.
6 Shingnaisui, K., Dey, T., Manna, P. and Kalita, J. 2018. Therapeutic potentials of Houttuynia cordata Thunb. against inflammation and oxidative stress: A review. J. Ethnopharmacol. 220, 35-43.   DOI
7 Traish, A. M. 2012. 5α-reductases in human physiology: an unfolding story. Endocr. Pract. 18, 965-975.   DOI
8 Van, A. B., Barkin, J. and Elterman, D. S. 2015. Medical therapy for benign prostatic hyperplasia: a review. Can. J. Urol. 1, 7-17.
9 Woodard, T. J., Manigault, K. R., McBurrows, N. N., Wray, T. L. and Woodard, L. M. 2016. Management of benign pro-static hyperplasia in older adults. Consult. Pharm. 31, 412-424.   DOI
10 Andriole, G., Bruchovsky, N., Chung, L. W., Matsumoto, A. M., Rittmaster, R., Roehrborn, C., Russell, D. and Tindall, D. 2004. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J. Urol. 172, 1399-1403.   DOI
11 Bisson, J. F., Hidalgo, S., Rozan, P. and Messaoudi, M. 2007. Therapeutic effect of ACTICOA powder, a cocoa polyphenolic extract, on experimentally induced prostate hyper plasia in Wistar-Unilever rats. J. Med. Food 10, 628-635.   DOI
12 Carson, C. and Rittmaster, R. 2003. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 61, 2-7.   DOI
13 Choi, Y. S., Lee, H. H., Lee, B. H. and Lee, S. Y. 1998. Effects of extracts of Houttuynia cordata Thunb on the level of lipids and lipid peroxidation in the liver and serum of cholesterol-fed rats. Kor. J. Plant. Res. 11, 173-178.
14 Foot, K. T. 2019. What is a disease? What is the disease clinical benign prostatic hyperplasia (BPH)? World J. Urol. 37, 1293-1296.   DOI
15 Huang, Y., Chen, H., Zhou, X., Wu, X., Hu, E. and Jiang, Z. 2017. Inhibition effects of chlorogenic acid on benign prostatic hyperplasia in mice. Euro. J. Pharmacol. 809, 191-195.   DOI
16 El-Demerdash, F. M., Yousef, M. I. and El-Naga, N. I. 2005. Biochemical study on the hypoglycemic effects of onion and garlic in alloxan-induced diabetic rats. Food Chem. Toxicol. 43, 57-63.   DOI
17 Choi, H. M., Jung, Y. U., Park, J. B., Kim, H. L., Youn, D. H., Kang, J. W., Jeong, M. Y., Lee, J. H., Yang, W. M., Lee, S. G., Ahn, K. S. and Um, J. Y. 2016. Cinnamomi cortex (cinnamomum verum) suppresses testosterone-induced benign prostatic hyperplasia by regulating 5α-reductase. Sci. Rep. 6, 31906.   DOI
18 Choi, B. R., Kim, H. K., Soni, K. K., Karna, K. K., Lee, S. W., So, I. and Park, J. K. 2018. Additive effect of oral lDD175 to tamsulosin and finasteride in a benign prostate hyperplasia rat model. Drug Des. Devel. Ther. 12, 1855-1863.   DOI
19 Mobley, D., Feibus, A. and Baum, N. 2015. Benign prostatic hyperplasia and urinary symptoms: Evaluation and treatment. Prostgrad. Med. 127, 301-307.   DOI
20 Nicholson, T. M. and Ricke, W. A. 2011. Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation 82, 184-199.   DOI
21 Keam, S. J. and Scott, L. J. 2008. Dutasteride: a review of its use in the management of prostate disorders. Drugs 68, 463-485.   DOI
22 Langan, R. C. 2019. Benign prostatic hyperplasia. Prime. Care 26, 223-232.   DOI
23 Azzouni, F. and Mohler, J. 2012. Role of 5α-reductase inhibitors in benign prostatic diseases. Prostate Cancer Prostatic Dis. 15, 222-230.   DOI
24 Richard, A., H., Zhong, H. Z., Dai, W., Dai, Q. and Liao, S. 2002. Structure-activity relationships for inhibition of human 5α-reductases by polyphenols. Biochem. Pharmacol. 63, 1165-1176.   DOI
25 Kim, H. M., Han, S. B., Oh, G. T., Kim, Y. H., Hong, D. H., Hong, N. D. and Yoo, I. D. 1996. Stimulation of humoral and cell mediated immunity by polysaccharide from mushroom Phellinus linteus. Int. J. Immunopharmacol. 18, 295-303.   DOI
26 Steers, W. D. 2001. 5alpha-reductase activity in the prostate. Urology 58, 17-24.   DOI
27 Ventura, S., Olier, V. L., White, C. W., Xie, J. H., Haynes, J. M. and Exintaris, B. 2011. Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH). Br. J. Pharmacol. 163, 891-907.   DOI
28 Madersbacher, S., Sampson, N. and Culig, Z. 2019. Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement: A Mini-Review. Gerontology 65, 458-464.   DOI
29 Moon, J. M., Sung, H. M., Jung, H. J., Seo, J. W. and Wee, J. H. 2017. In vivo evaluation of hot water extract of Acorus gramineus root against benign prostatic hyperplasia. BMC Complement. Altern. Med. 17, DOI:10.1186/s12906-017-1887-9.   DOI
30 Naresh, K. N., Aparna, B. and Veeresh, B. 2013. Protective effect of naringin on testosterone induced benign prostatic hyperplasia in rats. Intern. J. Pharm. Res. Scholars 2, 239-244